Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 5/20 | 0.34 |
| ▸ | ILK | Q13418 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | MYC | P01106 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18293323 | 0.96 | DRD2 (0.37) | DRD2KCNH2KDM4EKMT2AMEN1 | |
| SCHEMBL18293135 | 0.85 | KDM4E (0.47) | KDM4EKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL18293231 | 0.84 | APEX1 (0.48) | DRD2KDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL18286100 | 0.82 | LMNA (0.46) | DRD2KCNH2KDM4EKMT2AMEN1 | |
| SCHEMBL18285991 | 0.82 | APEX1 (0.51) | KDM4EKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL20239978 | 0.81 | MAPT (0.42) | DRD2KDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL18286085 | 0.80 | KDM4E (0.46) | KDM4EKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL18285792 | 0.77 | KDM4E (0.45) | KDM4EKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL18285856 | 0.76 | ADORA1 (0.52) | KDM4EKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL25456029 | 0.76 | ILK (0.36) | KDM4EKMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20210188833-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188833-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-10787444-B2 | Compounds for the modulation of myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10787444-B2 | Compounds for the modulation of myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-14 | — | — | US | disclosed |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-14 | — | — | US | disclosed |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-14 | — | — | US | disclosed |
| WO-2016197078-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | DRD2 4224/4885KCNH2 2201/4885KDM4E 4565/4885 |
| US-20210188833-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | DRD2 4018/4885KCNH2 1959/4885KDM4E 4623/4885 |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | MYC, MYCBP, MYCBP2 | DRD2 4018/4885KCNH2 1959/4885KDM4E 4623/4885 |
| US-10787444-B2 | Compounds for the modulation of myc activity | MYC, MYCBP, MYCBP2 | DRD2 4224/4885KCNH2 2201/4885KDM4E 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.